WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326721

CAS#: 101975-10-4

Description: Zardaverine is a Phosphodiesterase 3/4 inhibitor. Zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition. Zardaverine may be also useful for both, bronchorelaxation and reduction of inflammation in asthma therapy.

Price and Availability


USD 190

USD 350

USD 650

Zardaverine, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 326721
Name: Zardaverine
CAS#: 101975-10-4
Chemical Formula: C12H10F2N2O3
Exact Mass: 268.0659
Molecular Weight: 268.2198
Elemental Analysis: C, 53.74; H, 3.76; F, 14.17; N, 10.44; O, 17.89

Synonym: Zardaverine

IUPAC/Chemical Name: 6-(4-(Difluoromethoxy)-3-methoxyphenyl)-3(2H)-pyridazinone


InChi Code: InChI=1S/C12H10F2N2O3/c1-18-10-6-7(2-4-9(10)19-12(13)14)8-3-5-11(17)16-15-8/h2-6,12H,1H3,(H,16,17)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Sun L, Quan H, Xie C, Wang L, Hu Y, Lou L. Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition. PLoS One. 2014 Mar 5;9(3):e90627. doi: 10.1371/journal.pone.0090627. eCollection 2014. PubMed PMID: 24598942; PubMed Central PMCID: PMC3944092.

2: Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D. Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. PubMed PMID: 12952271.

3: Ukena D, Rentz K, Reiber C, Sybrecht GW. Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. Respir Med. 1995 Jul;89(6):441-4. PubMed PMID: 7644776.

4: Hoymann HG, Heinrich U, Beume R, Kilian U. Comparative investigation of the effects of zardaverine and theophylline on pulmonary function in rats. Exp Lung Res. 1994 May-Jun;20(3):235-50. PubMed PMID: 7925141.

5: Kips JC, Joos GF, Peleman RA, Pauwels RA. The effect of zardaverine, an inhibitor of phosphodiesterase isoenzymes III and IV, on endotoxin-induced airway changes in rats. Clin Exp Allergy. 1993 Jun;23(6):518-23. PubMed PMID: 8369979.

6: Schade FU, Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur J Pharmacol. 1993 Jan 5;230(1):9-14. PubMed PMID: 8381357.

7: Brunnée T, Engelstätter R, Steinijans VW, Kunkel G. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J. 1992 Sep;5(8):982-5. PubMed PMID: 1426207.

8: Huber R, Schildnitz U. Sensitive determination of the phosphodiesterase III/IV inhibitor zardaverine in human serum by direct sample injection, automated precolumn clean-up and high-performance liquid chromatography. J Chromatogr. 1991 Aug 16;553(1-2):65-70. PubMed PMID: 1787170.

9: Schudt C, Winder S, Müller B, Ukena D. Zardaverine as a selective inhibitor of phosphodiesterase isozymes. Biochem Pharmacol. 1991 Jun 21;42(1):153-62. PubMed PMID: 1648920.

10: Schudt C, Winder S, Eltze M, Kilian U, Beume R. Zardaverine: a cyclic AMP specific PDE III/IV inhibitor. Agents Actions Suppl. 1991;34:379-402. Review. PubMed PMID: 1665311.

11: Galvan M, Schudt C. Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle. Naunyn Schmiedebergs Arch Pharmacol. 1990 Aug;342(2):221-7. PubMed PMID: 1700309.